SCHEMBL23090407

SCHEMBL23090407

CCn1nc(C(F)(F)F)c(NC(=O)c2cc3c(cc2OC)CCCCC3)c1C

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 3/20 0.49
▸ SLC2A1 P11166 8/20 0.42
▸ SLC2A3 P11169 8/20 0.42
▸ SLC2A4 P14672 7/20 0.42
▸ SLC2A2 P11168 5/20 0.42
▸ CCR1 P32246 1/20 0.42
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ LMNA P02545 3/20 0.42
▸ MAPT P10636 2/20 0.42
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ TSHR P16473 2/20 0.40
▸ TP53 P04637 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23090414 0.78 DHODH (0.50) DHODHSMN1; SMN2LMNAMAPTMEN1
SCHEMBL21468483 0.74 LMNA (0.52) DHODHSMN1; SMN2LMNAMAPTMEN1
SCHEMBL23090396 0.72 DHODH (0.53) DHODHSMN1; SMN2LMNAMAPTMEN1
SCHEMBL13683140 0.70 CCR1 (0.45) SLC2A1SLC2A3SLC2A4SLC2A2CCR1
SCHEMBL23090376 0.69 DHODH (0.55) DHODHSMN1; SMN2LMNAMAPTMEN1
SCHEMBL21468520 0.68 DHODH (0.51) DHODHSMN1; SMN2LMNAMAPTMEN1
SCHEMBL23090385 0.67 DHODH (0.70) DHODHSMN1; SMN2LMNAMEN1KMT2A
SCHEMBL23090367 0.66 DHODH (1.00) DHODHSMN1; SMN2LMNAMAPTMEN1
SCHEMBL23090379 0.66 DHODH (0.78) DHODHSMN1; SMN2LMNAMAPTMEN1
SCHEMBL23090382 0.65 DHODH (1.00) DHODHSMN1; SMN2LMNAMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11066357-B2 Benzoannulene derivatives as antiviral agents SOUTHERN RESEARCH INSTITUTE (US) 2021-07-20 — — US disclosed
US-11066357-B2 Benzoannulene derivatives as antiviral agents SOUTHERN RESEARCH INSTITUTE (US) 2021-07-20 — — US disclosed
US-20210078937-A1 BENZOANNULENE DERIVATIVES AS ANTIVIRAL AGENTS SOUTHERN RESEARCH INSTITUTE 2021-03-18 — — US disclosed
US-20210078937-A1 BENZOANNULENE DERIVATIVES AS ANTIVIRAL AGENTS SOUTHERN RESEARCH INSTITUTE 2021-03-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210078937-A1 BENZOANNULENE DERIVATIVES AS ANTIVIRAL AGENTS ZC3HAV1, MAVS, ZC3HAV1L DHODH 344/4885SLC2A1 3161/4885SLC2A3 3030/4885
US-11066357-B2 Benzoannulene derivatives as antiviral agents ZC3HAV1, MAVS, ZC3HAV1L DHODH 344/4885SLC2A1 3161/4885SLC2A3 3030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback